Recent Updates
Recently added Catalysts

BL1107 Low dose

Phase 2

Glaucoma | Small molecule | Ophthalmology |Bausch + Lomb Corporation|Last Updated: May 7, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment252
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07168902Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular HypertensionPHASE2 ACTIVE NOT_RECRUITING 252 — — Oct 24, 2025May 1, 2026May 7, 202614 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change from baseline in visual field mean deviation in the study eye at Day 28/Exit.
Assessed at Day 28
Secondary Endpoints
Proportion of participants achieving ≥15-letter improvement in low-luminance best-corrected visual acuity (LL-BCVA) in the study eye at Day 28/Exit.
Assessed at Day 28
Proportion of participants achieving ≥10-letter improvement in low-luminance best-corrected visual acuity (LL-BCVA) in the study eye at Day 28/Exit.
Assessed at Day 28
Hour-matched change from Baseline in intraocular pressure (IOP) in the study eye at Day 28/Exit.
Assessed at Day 28
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
BL1107 Low doseEXPERIMENTAL -
BL1107 High doseEXPERIMENTAL -
Timolol maleate 0.5%ACTIVE_COMPARATOR -
Interventions
NameTypeDescription
BL1107 Low doseDRUGDosed twice daily for 28 days.
BL1107 High doseDRUGDosed twice daily for 28 days.
Timolol maleate 0.5%DRUGDosed twice daily for 28 days.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites14

Inclusion criteria: * Ocular hypertension or primary open-angle glaucoma in each eye Exclusion criteria: * History of orthostatic hypotension * Any active ocular disease * Anticipated wearing of contact lenses during study * Contraindication to pupil dilation

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Glaucoma 30 trials
CompanyTickerTrialsLead PhaseDrugs
Glaukos CorpGKOS6PHASE3Gen 2 Travoprost Intracameral, Timolol eye 0.5%, Travoprost
AbbVie, Inc.ABBV3PHASE3Bimatoprost, AGN-193408
SpyGlass Pharma, Inc.SGP4PHASE3Bimatoprost System, Timolol , 0.5%
Amneal Pharmaceuticals, Inc. Class AAMRX2PHASE3Test - Bimatoprost 0.01%, Reference - LUMIGAN, Bimatoprost , 0.01%, LUMIGAN 0.01%
Bausch + Lomb CorporationBLCO1PHASE2BL1107 Low dose, Timolol 0.5%
Alcon AGALC3NAUndisclosed
Sight Sciences, Inc.SGHT3 — Undisclosed
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
MEDIUMMay 26, 2026NCT07168902Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWMay 24, 2026NCT07168902studyFirstPostDate: changed